{
  "pmid": "35180413",
  "uid": "35180413",
  "title": "Fluvoxamine for the treatment of COVID-19 - Author's reply.",
  "abstract": "",
  "authors": [
    {
      "last_name": "Reis",
      "fore_name": "Gilmar",
      "initials": "G",
      "name": "Gilmar Reis",
      "affiliations": [
        "Gilmar Reis, Cardresearch - Cardiologia Assistencial e de Pesquisa, Brazil."
      ]
    },
    {
      "last_name": "Mills",
      "fore_name": "Edward",
      "initials": "E",
      "name": "Edward Mills",
      "affiliations": [
        "Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4K1, Canada. Electronic address: millsej@mcmaster.ca."
      ]
    }
  ],
  "journal": {
    "title": "The Lancet. Global health",
    "iso_abbreviation": "Lancet Glob Health",
    "issn": "2214-109X",
    "issn_type": "Electronic",
    "volume": "10",
    "issue": "3",
    "pub_year": "2022",
    "pub_month": "Mar"
  },
  "start_page": "e333",
  "pages": "e333",
  "language": "eng",
  "publication_types": [
    "Letter",
    "Comment"
  ],
  "keywords": [
    "Fluvoxamine",
    "Humans",
    "SARS-CoV-2",
    "COVID-19 Drug Treatment"
  ],
  "article_ids": {
    "pubmed": "35180413",
    "pmc": "PMC8846598",
    "doi": "10.1016/S2214-109X(21)00588-X",
    "pii": "S2214-109X(21)00588-X"
  },
  "doi": "10.1016/S2214-109X(21)00588-X",
  "pmc_id": "PMC8846598",
  "dates": {
    "completed": "2022-02-24",
    "revised": "2022-12-07"
  },
  "chemicals": [
    "Fluvoxamine"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T14:53:53.142779",
    "pmid": "35180413"
  }
}